Monika Maria Toernsen - 19 Jul 2021 Form 4 Insider Report for Passage BIO, Inc. (PASG)

Role
Chief Commercial Officer
Signature
/s/ Edgar Cale, Attorney-in-Fact
Issuer symbol
PASG
Transactions as of
19 Jul 2021
Net transactions value
$0
Form type
4
Filing time
21 Jul 2021, 18:54:24 UTC
Next filing
14 Feb 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PASG Employee Stock Option (Right to Buy) Award $0 +200,000 $0.000000 200,000 19 Jul 2021 Common Stock 200,000 $13.04 Direct F1
transaction PASG Restricted Stock Units Award $0 +20,000 $0.000000 20,000 19 Jul 2021 Common Stock 20,000 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 25% of the total shares on July 19, 2022, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on July 19, 2024, subject to the Reporting Person's provision of service to the issuer on each vesting date.
F2 Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
F3 1/4 of the RSUs will vest annually on September 15, 2022, and the remainder will vest as to 1/4 of the total award in annual installments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date.